• Medicus submitted an optimized seamless Phase 2b/3 registration-intent protocol to the FDA for Teverelix in advanced prostate cancer.
• Design uses a stage-gated start with about 80 randomized patients, expanding to about 608 total if continuation criteria are met.
• Plan targets a registrational pathway in patients at increased cardiovascular risk, aiming to cut prior enrollment plans from about 1,500 patients.
• Medicus plans to seek a partner to fund execution, pending FDA feedback on the proposed protocol.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Medicus Pharma Ltd. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609290730PRIMZONEFULLFEED9835613) on September 29, 2026, and is solely responsible for the information contained therein.